Analgesic Effect of Ibuprofen, Paracetamol (Acetaminophen), and Paracetamol (Acetaminophen) Plus Codeine on Acute Pain

This study has been completed.
Sponsor:
Collaborator:
University of Oslo
Information provided by:
Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT00699114
First received: June 12, 2008
Last updated: July 3, 2011
Last verified: February 2009
  Purpose

The purpose of this placebo controlled clinical trial is to evaluate the dose response relationship of ibuprofen in doses from 400 mg to 800 mg and paracetamol (acetaminophen)in doses from 500 mg to 1000 mg compared with paracetamol (acetaminophen)1000 mg plus codeine 60 mg on acute postoperative pain after surgical removal of impacted third molars.


Condition Intervention Phase
Surgery
Drug: Placebo
Drug: Ibuprofen 400 mg
Drug: Ibuprofen 600 mg
Drug: Ibuprofen 800 mg
Drug: Paracetamol (acetaminophen) 500 mg
Drug: Paracetamol (acetaminophen) 1000 mg
Drug: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Analgesic Effect of Ibuprofen 400, 600 and 800 mg, Paracetamol 500 and 1000 mg, and Paracetamol 1000 mg Plus 60 mg Codeine: Single-dose, Randomized, Placebo-controlled and Double-blind Study on Acute Pain After Third Molar Surgery

Resource links provided by NLM:


Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • Sum Pain Intensity Score(SPI) [ Time Frame: 3 hour observation period ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Sum Pain Intensity Difference Score (SPID) [ Time Frame: 3 hours ] [ Designated as safety issue: No ]
  • Sum Pain Intensity Score (SPI) [ Time Frame: 6 hours ] [ Designated as safety issue: No ]
  • Sum Pain Intensity Difference Score (SPID) [ Time Frame: 6 hours ] [ Designated as safety issue: No ]
  • Maximum Pain Intensity Difference Score (MAXPID) [ Time Frame: Unknown, calculated variable ] [ Designated as safety issue: No ]
  • Time to Maximum Pain Intensity Difference Score [ Time Frame: Unknown, calculated variable ] [ Designated as safety issue: No ]
  • Self-reported Occurrence of Adverse Effects [ Time Frame: 3 hours ] [ Designated as safety issue: Yes ]
  • Self-reported Occurrence of Adverse Effects [ Time Frame: 6 hours ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 350
Study Start Date: June 2007
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Single dose placebo capsule
Drug: Placebo
Lactose as powder in gelatine capsules, single dose
Other Name: Lactose
Active Comparator: Ibuprofen 400 mg
Single dose ibuprofen 400 mg capsule
Drug: Ibuprofen 400 mg
Ibuprofen 400 mg as powder in gelatine capsules, single dose
Other Name: M01A E01 Ibuprofen
Active Comparator: Ibuprofen 600 mg
Single dose ibuprofen 600 mg capsule
Drug: Ibuprofen 600 mg
Ibuprofen 600 mg as powder in gelatine capsules, single dose
Other Name: M01A E01 Ibuprofen
Active Comparator: Ibuprofen 800 mg
Single dose ibuprofen 800 mg capsule
Drug: Ibuprofen 800 mg
Ibuprofen 800 mg as powder in gelatine capsules, single dose
Other Name: M01A E01 Ibuprofen
Active Comparator: Paracetamol 500 mg
Paracetamol 500 mg (acetaminophen) capsule
Drug: Paracetamol (acetaminophen) 500 mg
Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose
Other Name: N02B E01 Paracetamol (acetaminophen)
Active Comparator: Paracetamol 1000 mg
Single dose paracetamol 1000 mg (acetaminophen) capsule
Drug: Paracetamol (acetaminophen) 1000 mg
Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose
Other Name: N02B E01 Paracetamol (acetaminophen)
Active Comparator: Paracetamol 1000 mg + codeine 60 mg
Single dose paracetamol (acetaminophen) 1000 mg + codeine 60 mg capsule
Drug: Paracetamol (acetaminophen) 1000 mg + codeine 60 mg
Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
Other Name: N02B E01 Paracetamol (acetaminophen) + R05D A04 codeine

Detailed Description:

Acetaminophen (paracetamol) and related aspirin-like drugs have traditionally been used for pain control of minor to moderate postoperative pain. Gradually traditional non-steroidal anti-inflammatory drugs (NSAIDs) have become more popular as analgesics due to assumed superior therapeutic effects and aggressive marketing campaigns orchestrated by the pharmaceutical industry.

Ibuprofen is a widely used analgesic both in non-prescription and prescription doses.

A dose-response relationship for low ibuprofen doses is shown. Evidence of a progressing dose response relationship for moderate (i.e. 400 mg) to higher doses is scarce. A possible analgesic ceiling effect has been suggested for doses above 400 mg, although a correlation between given ibuprofen doses above 400 mg and patient serum levels is shown. However, it may be questioned if the plasma concentration of ibuprofen is an important determinator of analgesic drug efficacy. A higher dose is more likely to influence the duration of analgesic effect rather than the peak analgesic effect.

There are few clinical trials investigating the dose-response relationship of increasing ibuprofen doses and paracetamol doses. To our knowledge no published study has investigated the dose-response relationship of ibuprofen and paracetamol in the same trial with a negative (i.e. placebo) and a positive (i.e. best standard analgesic treatment) control group.

  Eligibility

Ages Eligible for Study:   18 Years to 30 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients of both sexes referred for surgical removal of impacted third molars, due to symptoms or after being advised to do so by their dentist.
  • Persons of both sexes (ASA type I).
  • Females who are not pregnant or plan conception.
  • Persons who have not used analgesics for 3 days prior to the day of surgery.
  • Persons without known active ulcus or gastrointestinal bleeding.
  • Persons without any known hypersensitivity for NSAIDs.
  • Persons under no other continuous drug treatment than contraceptives.
  • Caucasian origin.
  • Persons with at least moderate postoperative pain as defined by subjective score on a verbal rating scale after surgical removal of third molars.

Exclusion Criteria:

  • Patients with surgery time exceeding 60 minutes
  • Peroperative complications such as profuse bleeding or perforation to the maxillary sinus requiring additional drug treatment during or after the surgical removal of the third molar.
  • Postoperative complications such as extended bleeding, nausea and regurgitation during the observation period.
  • Smoking before taking the test-drug or during the observation period.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00699114

Locations
Norway
Department of Oral and Maxillofacial Surgery, Ullevaal University Hospital
Oslo, Norway, N-0407
Sponsors and Collaborators
Ullevaal University Hospital
University of Oslo
Investigators
Study Chair: Lasse A Skoglund, DDS, DSCi Section of Dental Pharmacology and Pharmacotherapy, ICD, Faculty of Dentistry, University of Oslo, POB 1119 Blindern, N-0317 Oslo, Norway
Study Director: Per Skjelbred, MD, DDS, PhD Department of Oral and Maxillofacial Surgery, Ullevaal University Hospital, Kirkeveien 166, N-0407 Oslo, Norway
Principal Investigator: Gaute Lyngstad, DDS Section of Dental Pharmacology and Pharmacotherapy, ICD, Faculty of Dentistry, University of Oslo, POB 1119 Blindern, N0317 Oslo, Norway
  More Information

No publications provided

Responsible Party: Professor Lasse A. Skoglund, DDS, DSci, University of Oslo
ClinicalTrials.gov Identifier: NCT00699114     History of Changes
Other Study ID Numbers: PARIBU-020
Study First Received: June 12, 2008
Last Updated: July 3, 2011
Health Authority: Norway: Norwegian Medicines Agency
Norway: Norwegian Social Science Data Services

Keywords provided by Oslo University Hospital:
Pain
Analgesics
Molar
Third
Acetaminophen
Paracetamol
Ibuprofen
Codeine
Placebo

Additional relevant MeSH terms:
Acetaminophen
Ibuprofen
Analgesics
Codeine
Antipyretics
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Analgesics, Opioid
Central Nervous System Depressants
Antitussive Agents
Respiratory System Agents
Narcotics
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 17, 2014